ERAS
Price
$2.08
Change
+$0.27 (+14.92%)
Updated
Sep 26 closing price
Capitalization
590.03M
38 days until earnings call
REPL
Price
$4.13
Change
+$0.08 (+1.98%)
Updated
Sep 26 closing price
Capitalization
322.37M
51 days until earnings call
Interact to see
Advertisement

ERAS vs REPL

Header iconERAS vs REPL Comparison
Open Charts ERAS vs REPLBanner chart's image
Erasca
Price$2.08
Change+$0.27 (+14.92%)
Volume$2.54M
Capitalization590.03M
Replimune Group
Price$4.13
Change+$0.08 (+1.98%)
Volume$2.38M
Capitalization322.37M
ERAS vs REPL Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. REPL commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a StrongBuy and REPL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (ERAS: $2.08 vs. REPL: $4.13)
Brand notoriety: ERAS and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 260% vs. REPL: 22%
Market capitalization -- ERAS: $590.03M vs. REPL: $322.37M
ERAS [@Biotechnology] is valued at $590.03M. REPL’s [@Biotechnology] market capitalization is $322.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 5 bearish.
  • REPL’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, REPL is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +13.04% price change this week, while REPL (@Biotechnology) price change was +28.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($590M) has a higher market cap than REPL($322M). ERAS YTD gains are higher at: -17.131 vs. REPL (-65.896). ERAS has higher annual earnings (EBITDA): -135.93M vs. REPL (-268.18M). REPL has more cash in the bank: 403M vs. ERAS (301M). ERAS has less debt than REPL: ERAS (49.4M) vs REPL (76.3M). ERAS (0) and REPL (0) have equivalent revenues.
ERASREPLERAS / REPL
Capitalization590M322M183%
EBITDA-135.93M-268.18M51%
Gain YTD-17.131-65.89626%
P/E RatioN/AN/A-
Revenue00-
Total Cash301M403M75%
Total Debt49.4M76.3M65%
FUNDAMENTALS RATINGS
REPL: Fundamental Ratings
REPL
OUTLOOK RATING
1..100
64
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASREPL
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CUSRX14.480.17
+1.19%
Cullen Small Cap Value Retail
TSVCX11.030.10
+0.91%
Timothy Plan Small Cap Value C
OBSOX28.110.22
+0.79%
Oberweis Small-Cap Opportunities
AAERX19.110.12
+0.63%
American Beacon International Eq R6
PRJDX49.030.04
+0.08%
PGIM Jennison Global Opportunities R4

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+14.92%
XNCR - ERAS
56%
Loosely correlated
+12.00%
OCUL - ERAS
54%
Loosely correlated
+2.37%
RVMD - ERAS
50%
Loosely correlated
+3.32%
BEAM - ERAS
50%
Loosely correlated
-0.52%
CRNX - ERAS
50%
Loosely correlated
+27.92%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+1.98%
IMNN - REPL
56%
Loosely correlated
-0.19%
SNDX - REPL
49%
Loosely correlated
+4.32%
KYMR - REPL
46%
Loosely correlated
+4.68%
ERAS - REPL
44%
Loosely correlated
+14.92%
BEAM - REPL
43%
Loosely correlated
-0.52%
More